The following information is the translation of the manufacturer's insert. It is provided under the supplying company's terms and conditions and should not replace the advice of your personal physician.

ANIRACETAM (Draganon)

Chemical

Aniracetam. This is an original pharmaceutical product by Roche, which acts on the central nervous system (CNS), stimulating the learning process and the memory. Pharmacological studies have shown that Aniracetam stimulates the functions of certain neuronal receptors by means of glutamic acid, bringing about memorization processes (AMPA receptors) and protection of nerve cells (metabotrophic receptors). Clinical studies have shown specific therapeutic activity in elderly patients affected by alterations of the cognitive functions. Both long and short term memory improvement have seen in addition to learning, attention span, alertness, concentration, reasoning and absent mindedness.

Draganon is Recommended For

Attention and memory disorders of a degenerative or vascular origin in the elderly.

Contraindications

Individual hypersensitivity to the product.

Precautions and Special Warnings

In the case of unrest, anxiety, agitation in the evening or insomnia, it is advisable for the patient to take the second dose in the early hours of the afternoon or even one single 1500 mg dose in the morning. Although animal research has shown no teratogenic effects, taking this product during pregnancy or while nursing is still inadvisable. In patients suffering from serious renal insufficiency (creatine clearance < 10 ml/min), the daily dosage should be lowered.

Interactions

Clinical experience has shown no pharmacological interactions between Draganon and other pharmaceutical products.

Directions for Use

The total recommended dosage is 1500 mg per day to be taken in 1 or 2 doses. The tablets are to be taken whole accompanied by water. The contents of the powder packets are to be dissolved in a half glass of water. The therapeutic effect of Aniracetam is seen after about 60 days and may be more pronounced after 4 months of treatment.

Overdose

Cases of overdose of this pharmaceutical product have not been reported.

Unpleasant Side Effects

Draganon is well tolerated by all patients, even the elderly. Although occasional signs of agitation, anxiety, unrest, insomnia have been reported, these side effects subside if treatment is modified (see precautions and warnings). Rare side effects have been reported of headache, a sense of epigastric heaviness, drowsiness, asthenia and dizziness. Should you experience any side effects not described here consult your physician.

Expiry Date

Do not use this product after the expiry date has passed.

Keep out of the reach of children.